 |
|
|
| |
Week 26 Interim Analysis of Implementation and Delivery of Long-Acting Injectable Cabotegravir for PrEP in a Community Pharmacy Setting
|
| |
| |
Methods:
This is a 26-week interim analysis of an observational, mixed methods study of 50 participants who have enrolled and been in care at Kelley-Ross Pharmacy in Seattle, Washington from June 1, 2023, to April 26, 2024. The protocol was approved by the institutional review board. Data was collected from both patient surveys and retrospective chart review by study investigators. Participants completed a baseline survey and benefits investigation for CAB-LA for PrEP after enrollment. Follow up surveys were collected at every visit, including early discontinuation. Feasibility outcomes include proportion of participants recruited and retained in PrEP care and adherence (Table 2). Acceptability outcome of patient satisfaction is measured through qualitative data generated from surveys, represented as a Likert scale quantified with variance applied (Figure 2).
|
| |
|
|
|
|
|
